EX-99.2 3 a2023q1exhibit992.htm EX-99.2

Exhibit 99.2

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)			FIRST QUARTER
															Percent Change
			2023						2022						Total						Operations						Currency
Sales to customers by
geographic area
U.S.			$	12,517					11,414						9.7			%			9.7						—
Europe			6,332						6,024						5.1						10.0						(4.9)
Western Hemisphere excluding U.S.			1,587						1,482						7.1						14.3						(7.2)
Asia-Pacific, Africa			4,310						4,506						(4.3)						4.1						(8.4)
International			12,229						12,012						1.8						8.3						(6.5)
Worldwide			$	24,746					23,426						5.6			%			9.0						(3.4)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

---

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)			FIRST QUARTER
															Percent Change
			2023						2022						Total						Operations						Currency
Sales to customers by
segment of business
Consumer Health
U.S.			$	1,735					1,557						11.4			%			11.4						—
International			2,117						2,029						4.4						11.3						(6.9)
			3,852						3,586						7.4						11.3						(3.9)
Pharmaceutical (1)
U.S.			7,023						6,632						5.9						5.9						—
International			6,390						6,237						2.4						8.6						(6.2)
			13,413						12,869						4.2						7.2						(3.0)
Pharmaceutical excluding COVID-19 Vaccine (1)
U.S.			7,023						6,557						7.1						7.1						—
International			5,643						5,855						(3.6)						2.4						(6.0)
			12,666						12,412						2.0						4.9						(2.9)
MedTech (1)
U.S.			3,759						3,225						16.6						16.6						—
International			3,722						3,746						(0.6)						6.2						(6.8)
			7,481						6,971						7.3						11.0						(3.7)
U.S.			12,517						11,414						9.7						9.7						—
International			12,229						12,012						1.8						8.3						(6.5)
Worldwide			24,746						23,426						5.6						9.0						(3.4)
U.S.			12,517						11,339						10.4						10.4						—
International			11,482						11,630						(1.3)						5.2						(6.5)
Worldwide excluding COVID-19 Vaccine (1)			$	23,999					22,969						4.5			%			7.7						(3.2)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales reconciliation schedule.

---

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)			FIRST QUARTER
			2023												2022												Percent
									Percent												Percent						Increase
			Amount						to Sales						Amount						to Sales						(Decrease)
Sales to customers			$	24,746					100.0						$	23,426					100.0						5.6
Cost of products sold			8,395						33.9						7,598						32.4						10.5
Gross Profit			16,351						66.1						15,828						67.6						3.3
Selling, marketing and administrative expenses			6,138						24.8						5,938						25.4						3.4
Research and development expense			3,563						14.4						3,462						14.8						2.9
In-process research and development			49						0.2						610						2.6
Interest (income) expense, net			(20)						(0.1)						(12)						(0.1)
Other (income) expense, net			7,228						29.2						(102)						(0.4)
Restructuring			130						0.6						70						0.3
Earnings/(Loss) before provision for taxes on income			(737)						(3.0)						5,862						25.0						(112.6)
Provision for/(Benefit from) taxes on income			(669)						(2.7)						713						3.0						(193.8)
Net earnings/(Loss)			$	(68)					(0.3)						$	5,149					22.0						(101.3)
Net earnings/(Loss) per share (Basic/Diluted)*			$	(0.03)											$	1.93											(101.6)
Average shares outstanding (Basic/Diluted)*			2,605.5												2,666.5
Effective tax rate			90.8			%									12.2			%
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income			$	8,468					34.2						$	8,218					35.1						3.0
Net earnings			$	7,068					28.6						$	7,129					30.4						(0.9)
Net earnings per share (Diluted)			$	2.68											$	2.67											0.4
Average shares outstanding (Diluted)**			2,634.3												2,666.5
Effective tax rate			16.5			%									13.3			%
* Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutive.
** Difference of 28.8 shares due to anti-dilutive impact on net loss position.
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

---

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
						First Quarter
			(Dollars in Millions Except Per Share Data)			2023						2022
			Net Earnings/(Loss), after tax- as reported			$	(68)					$	5,149
			Pre-tax Adjustments
			Litigation expense			6,900						-
			Intangible Asset Amortization expense			1,204						1,108
			COVID-19 Vaccine related costs1			444						-
			Consumer Health separation costs			300						102
			Restructuring related2			130						72
			(Gains)/losses on securities			72						411
			Medical Device Regulation3			64						60
			IPR&D			49						610
			Acquisition, integration and divestiture related			42						-
			Other			-						(7)
			Tax Adjustments
			Tax impact on special item adjustments 4			(2,057)						(393)
			Consumer Health separation tax related costs			11						96
			Tax legislation and other tax related			(23)						(79)
			Adjusted Net Earnings, after tax			$	7,068					$	7,129
			Average shares outstanding (Diluted)			2,634.3						2,666.5
			Adjusted net earnings per share (Diluted)			$	2.68					$	2.67
			Operational adjusted net earnings per share (Diluted)			$	2.75
			Notes:
1			COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments.
2			In the first quarter of 2023, the company completed a prioritization of its research and development (R&D) investment within the Pharmaceutical segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, HIV and hepatitis. The restructuring expenses of $130 million in the quarter include the termination of partnered and non-partnered program costs and asset impairments.
3			European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024.
4			The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

---

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
FIRST QUARTER 2023 ACTUAL vs. 2022 ACTUAL
Segments
						Consumer Health						Pharmaceutical						MedTech						Total
WW As Reported						7.4		%				4.2		%				7.3		%				5.6		%
U.S.						11.4		%				5.9		%				16.6		%				9.7		%
International						4.4		%				2.4		%				(0.6)		%				1.8		%
WW Currency						(3.9)						(3.0)						(3.7)						(3.4)
U.S.						—						—						—						—
International						(6.9)						(6.2)						(6.8)						(6.5)
WW Operational						11.3		%				7.2		%				11.0		%				9.0		%
U.S.						11.4		%				5.9		%				16.6		%				9.7		%
International						11.3		%				8.6		%				6.2		%				8.3		%
Abiomed																		(4.6)						(1.4)
U.S.																		(8.2)						(2.3)
International																		(1.6)						(0.5)
All Other Acquisitions and Divestitures						0.0						0.0						0.0						0.0
U.S.						0.0						0.0						0.0						0.0
International						0.0						0.2						0.0						0.1
WW Adjusted Operational						11.3		%				7.2		%				6.4		%				7.6		%
U.S.						11.4		%				5.9		%				8.4		%				7.4		%
International						11.3		%				8.8		%				4.6		%				7.9		%
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.

---

Johnson & Johnson
Segment Sales
(Dollars in Millions)
									FIRST QUARTER
																					% Change
									2023						2022						Reported			Operational (1)			Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US						$			745						670						11.0		%	11.0		%	—		%
Intl									897						791						13.5			19.8			(6.3)
WW									1,642						1,461						12.4			15.8			(3.4)
SKIN HEALTH / BEAUTY
US									617						544						13.4			13.4			—
Intl									493						468						5.3			12.6			(7.3)
WW									1,110						1,012						9.7			13.1			(3.4)
ORAL CARE
US									159						143						11.6			11.6			—
Intl									202						223						(9.6)			(4.0)			(5.6)
WW									361						366						(1.3)			2.1			(3.4)
BABY CARE
US									96						85						13.0			13.0			—
Intl									263						270						(2.8)			4.5			(7.3)
WW									359						355						1.0			6.5			(5.5)
WOMEN'S HEALTH
US									3						3						1.8			1.8			—
Intl									214						224						(4.9)			4.1			(9.0)
WW									217						228						(4.8)			4.1			(8.9)
WOUND CARE / OTHER
US									115						112						2.6			2.6			—
Intl									49						52						(6.0)			2.3			(8.3)
WW									164						164						(0.1)			2.5			(2.6)
TOTAL CONSUMER HEALTH
US									1,735						1,557						11.4			11.4			—
Intl									2,117						2,029						4.4			11.3			(6.9)
WW						$			3,852						3,586						7.4		%	11.3		%	(3.9)		%
See footnotes at end of schedule

---

Johnson & Johnson
Segment Sales
(Dollars in Millions)
									FIRST QUARTER
																					% Change
									2023						2022						Reported			Operational (1)			Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US						$			2,448						2,501						(2.1)		%	(2.1)		%	—		%
Intl									1,664						1,617						2.9			9.7			(6.8)
WW									4,112						4,119						(0.2)			2.5			(2.7)
REMICADE
US									276						358						(22.8)			(22.8)			—
US Exports (4)									41						80						(48.8)			(48.8)			—
Intl									170						225						(24.4)			(20.0)			(4.4)
WW									487						663						(26.5)			(25.0)			(1.5)
SIMPONI / SIMPONI ARIA
US									271						287						(5.6)			(5.6)			—
Intl									266						283						(6.1)			1.8			(7.9)
WW									537						571						(5.8)			(1.9)			(3.9)
STELARA
US									1,451						1,379						5.2			5.2			—
Intl									993						909						9.3			16.2			(6.9)
WW									2,444						2,288						6.8			9.6			(2.8)
TREMFYA
US									406						391						3.9			3.9			—
Intl									234						199						17.3			24.9			(7.6)
WW									640						590						8.4			11.0			(2.6)
OTHER IMMUNOLOGY
US									3						6						(51.2)			(51.2)			—
Intl									0						0						—			—			—
WW									3						6						(51.3)			(51.3)			0.0
INFECTIOUS DISEASES
US									392						461						(14.9)			(14.9)			—
Intl									1,193						836						42.8			49.2			(6.4)
WW									1,586						1,297						22.3			26.4			(4.1)
COVID-19 VACCINE
US									0						75						*			*			—
Intl									747						382						95.6			*			(8.9)
WW									747						457						63.4			70.8			(7.4)
EDURANT / rilpivirine
US									9						9						(1.4)			(1.4)			—
Intl									271						239						13.4			18.7			(5.3)
WW									280						248						12.8			18.0			(5.2)
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US									378						369						2.5			2.5			—
Intl									99						132						(25.2)			(21.2)			(4.0)
WW									477						501						(4.8)			(3.7)			(1.1)
OTHER INFECTIOUS DISEASES
US									5						8						(33.1)			(33.1)			—
Intl									77						83						(7.6)			(5.6)			(2.0)
WW									82						91						(9.8)			(8.0)			(1.8)
See footnotes at end of schedule

---

Johnson & Johnson
Segment Sales
(Dollars in Millions)
									FIRST QUARTER
																					% Change
									2023						2022						Reported			Operational (1)			Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
NEUROSCIENCE
US						$			978						843						16.0%			16.0%			—%
Intl									826						898						(8.1)			(3.1)			(5.0)
WW									1,804						1,741						3.6			6.1			(2.5)
CONCERTA / methylphenidate
US									70						35						*			*			—
Intl									136						122						11.4			20.2			(8.8)
WW									206						157						31.4			38.2			(6.8)
INVEGA SUSTENNA / XEPLION / INVEGA
TRINZA / TREVICTA
US									713						661						7.9			7.9			—
Intl									331						387						(14.6)			(8.9)			(5.7)
WW									1,044						1,048						(0.4)			1.7			(2.1)
SPRAVATO
US									111						61						82.4			82.4			—
Intl									20						9						*			*			*
WW									131						70						86.9			88.0			(1.1)
OTHER NEUROSCIENCE
US									84						86						(3.5)			(3.5)			—
Intl									339						380						(10.7)			(7.6)			(3.1)
WW									423						467						(9.4)			(6.9)			(2.5)
ONCOLOGY
US									1,889						1,582						19.4			19.4			—
Intl									2,223						2,369						(6.1)			(0.1)			(6.0)
WW									4,112						3,950						4.1			7.7			(3.6)
CARVYKTI
US									70						—						*			*			—
Intl									2						—						*			*			—
WW									72						—						*			*			—
DARZALEX
US									1,191						953						25.0			25.0			—
Intl									1,072						903						18.8			26.4			(7.6)
WW									2,264						1,856						22.0			25.7			(3.7)
ERLEADA
US									249						206						21.2			21.2			—
Intl									293						194						50.9			60.7			(9.8)
WW									542						400						35.6			40.3			(4.7)
IMBRUVICA
US									270						370						(27.1)			(27.1)			—
Intl									557						668						(16.6)			(11.7)			(4.9)
WW									827						1,038						(20.3)			(17.2)			(3.1)
ZYTIGA / abiraterone acetate
US									16						19						(14.0)			(14.0)			—
Intl									229						520						(56.0)			(52.2)			(3.8)
WW									245						539						(54.5)			(50.9)			(3.6)
OTHER ONCOLOGY
US									92						34						*			*			—
Intl									70						84						(17.2)			(12.1)			(5.1)
WW									162						118						37.4			41.0			(3.6)
See footnotes at end of schedule

---

Johnson & Johnson
Segment Sales
(Dollars in Millions)
									FIRST QUARTER
																					% Change
									2023						2022						Reported			Operational (1)			Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
PULMONARY HYPERTENSION
US						$			600						572						4.9		%	4.9		%	—		%
Intl									272						279						(2.7)			5.3			(8.0)
WW									872						852						2.4			5.0			(2.6)
OPSUMIT
US									273						273						(0.1)			(0.1)			—
Intl									167						170						(1.6)			6.1			(7.7)
WW									440						443						(0.7)			2.3			(3.0)
UPTRAVI
US									304						269						13.1			13.1			—
Intl									58						56						3.3			9.4			(6.1)
WW									362						325						11.4			12.4			(1.0)
OTHER PULMONARY HYPERTENSION
US									23						30						(22.4)			(22.4)			—
Intl									47						53						(12.6)			(1.8)			(10.8)
WW									70						83						(16.1)			(9.3)			(6.8)
CARDIOVASCULAR / METABOLISM / OTHER
US									715						672						6.3			6.3			—
Intl									212						238						(10.8)			(6.3)			(4.5)
WW									927						910						1.8			3.0			(1.2)
XARELTO
US									578						508						13.7			13.7			—
Intl									—						—						—			—			—
WW									578						508						13.7			13.7			—
OTHER
US									137						164						(16.7)			(16.7)			—
Intl									212						238						(10.8)			(6.3)			(4.5)
WW									349						402						(13.2)			(10.5)			(2.7)
TOTAL PHARMACEUTICAL
US									7,023						6,632						5.9			5.9			—
Intl									6,390						6,237						2.4			8.6			(6.2)
WW						$			13,413						12,869						4.2		%	7.2		%	(3.0)		%
See footnotes at end of schedule

---

Johnson & Johnson
Segment Sales
(Dollars in Millions)
									FIRST QUARTER
																					% Change
									2023						2022						Reported			Operational (1)			Currency
MEDTECH SEGMENT (2) (3)
INTERVENTIONAL SOLUTIONS
US						$			863						494						74.5		%	74.5		%	—		%
Intl									640						597						7.1			14.9			(7.8)
WW									1,503						1,092						37.6			41.9			(4.3)
ELECTROPHYSIOLOGY
US									571						470						21.4			21.4			—
Intl									522						532						(1.8)			6.1			(7.9)
WW									1,092						1,002						9.1			13.3			(4.2)
ABIOMED
US									264						—						*			*			—
Intl									60						—						*			*			—
WW									324						—						*			*			—
OTHER INTERVENTIONAL SOLUTIONS
US									28						24						17.4			17.4			—
Intl									58						65						(11.7)			(5.0)			(6.7)
WW									87						90						(3.9)			1.1			(5.0)
ORTHOPAEDICS
US									1,363						1,289						5.8			5.8			—
Intl									881						899						(2.0)			4.0			(6.0)
WW									2,245						2,188						2.6			5.1			(2.5)
HIPS
US									241						225						7.3			7.3			—
Intl									149						164						(9.0)			(3.6)			(5.4)
WW									390						389						0.4			2.7			(2.3)
KNEES
US									226						201						12.4			12.4			—
Intl									142						138						3.4			9.6			(6.2)
WW									368						339						8.7			11.3			(2.6)
TRAUMA
US									491						475						3.2			3.2			—
Intl									267						273						(2.4)			3.6			(6.0)
WW									757						748						1.2			3.4			(2.2)
SPINE, SPORTS & OTHER
US									406						387						4.7			4.7			—
Intl									323						324						(0.3)			5.9			(6.2)
WW									729						712						2.4			5.2			(2.8)
See footnotes at end of schedule

---

Johnson & Johnson
Segment Sales
(Dollars in Millions)
									FIRST QUARTER
																					% Change
									2023						2022						Reported			Operational (1)			Currency
MEDTECH SEGMENT (2) (3) (Continued)
SURGERY
US						$			975						921						5.9		%	5.9		%	—		%
Intl									1,459						1,513						(3.6)			3.1			(6.7)
WW									2,434						2,434						0.0			4.1			(4.1)
ADVANCED
US									444						417						6.5			6.5			—
Intl									673						729						(7.6)			(1.1)			(6.5)
WW									1,118						1,146						(2.5)			1.6			(4.1)
GENERAL
US									531						504						5.4			5.4			—
Intl									785						784						0.2			7.0			(6.8)
WW									1,316						1,288						2.2			6.4			(4.2)
VISION
US									558						521						7.1			7.1			—
Intl									743						736						0.8			8.0			(7.2)
WW									1,300						1,257						3.4			7.6			(4.2)
CONTACT LENSES / OTHER
US									444						400						11.1			11.1			—
Intl									509						511						(0.3)			7.9			(8.2)
WW									953						910						4.7			9.3			(4.6)
SURGICAL
US									114						121						(6.0)			(6.0)			—
Intl									233						226						3.3			8.0			(4.7)
WW									347						347						0.1			3.1			(3.0)
TOTAL MEDTECH
US									3,759						3,225						16.6			16.6			—
Intl									3,722						3,746						(0.6)			6.2			(6.8)
WW						$			7,481						6,971						7.3		%	11.0		%	(3.7)		%
See footnotes at end of schedule
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-
rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures; refer to supplemental sales schedules
(4) Reported as U.S. sales

---

Supplemental Sales Reconciliation (Unaudited)
(Dollars in Millions)
									FIRST QUARTER
																					Percent Change
									2023						2022						Total						Operations						Currency
			Pharmaceutical
			U.S.						$	7,023					6,632						5.9			%			5.9						-
			International						6,390						6,237						2.4						8.6						(6.2)
			Worldwide						13,413						12,869						4.2						7.2						(3.0)
			COVID-19 Vaccine
			U.S.						0						75						*						*						-
			International						747						382						95.6						*						(8.9)
			Worldwide						747						457						63.4						70.8						(7.4)
			Pharmaceutical excluding COVID-19 Vaccine
			U.S.						7,023						6,557						7.1						7.1						-
			International						5,643						5,855						(3.6)						2.4						(6.0)
			Worldwide						12,666						12,412						2.0						4.9						(2.9)
			Worldwide
			U.S.						12,517						11,414						9.7						9.7						-
			International						12,229						12,012						1.8						8.3						(6.5)
			Worldwide						24,746						23,426						5.6						9.0						(3.4)
			COVID-19 Vaccine
			U.S.						0						75						*						*						-
			International						747						382						95.6						*						(8.9)
			Worldwide						747						457						63.4						70.8						(7.4)
			Worldwide
			U.S.						12,517						11,339						10.4						10.4						-
			International						11,482						11,630						(1.3)						5.2						(6.5)
			Worldwide excluding COVID-19 Vaccine						$	23,999					22,969						4.5			%			7.7						(3.2)
			Note: Columns and rows within tables may not add due to rounding
			* Percentage greater than 100% or not meaningful

---

Johnson & Johnson
Supplemental Sales Information
(Dollars in Millions)
Certain prior year amounts have been reclassified to
conform to current year product disclosures
			2021						2022																								2022
			Full Year						Q1						Q2						Q3						Q4						Full Year
PHARMACEUTICAL SEGMENT (1)
NEUROSCIENCE (2)
SPRAVATO
US			$	198					61						74						88						105						328
INTL			26						9						11						12						14						46
WW			224						70						85						100						119						374
OTHER NEUROSCIENCE (2)
US			427						86						93						106						91						376
Intl			1,647						380						341						286						351						1,358
WW			2,074						467						433						393						442						1,734
ONCOLOGY
CARVYKTI
US			—						—						24						55						54						133
INTL			—						—						—						—						—						—
WW			—						—						24						55						54						133
OTHER ONCOLOGY
US			110						34						33						37						52						156
INTL			458						84						72						64						63						283
WW			568						118						106						100						114						438
CARDIOVASCULAR / METABOLISM / OTHER
OTHER (3)
US			754						164						148						147						110						569
INTL			927						238						215						198						194						845
WW			1,682						402						363						345						304						1,414
MEDTECH SEGMENT (1)
INTERVENTIONAL SOLUTIONS
ELECTROPHYSIOLOGY			1,730						470						499						520						547						2,036
US			1,893						532						469						453						447						1,901
INTL			3,623						1,002						968						973						994						3,937
WW
ABIOMED (4)
US			—						—						—						—						31						31
INTL			—						—						—						—						—						—
WW			—						—						—						—						31						31
OTHER INTERVENTIONAL SOLUTIONS
US			106						24						26						27						25						102
Intl			242						65						56						60						48						230
WW			$	348					90						81						87						73						332
Note: Columns and rows within tables may not add due to rounding.
(1) Unaudited
(2) Other Neuroscience is inclusive of RISPERDAL CONSTA, which was previously disclosed separately
(3) Other is inclusive of INVOKANA, which was previously disclosed separately
(4) Acquired on December 22, 2022